Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431–438

Chaldakov, George N.; Tonchev, Anton B.; Manni, Luigi; Hristova, Mariyana G.; Nikolova, Vesselka; Fiore, M.; Vyagova, D.; Peneva, V. N.; Aloe, Luigi

doi:10.1007/s00125-007-0706-0

Cited by 21 publications

(6 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interestingly, plasma BDNF levels are decreased in patients with diabetes mellitus type 2 (DM2) and have been inversely correlated with plasma glucose and insulin resistance as assessed by homeostatic model assessment. Moreover, the output of plasma BDNF from the human brain is abrogated by hyperglycemia, but it is not regulated by hyperinsulinemia[5]. …”

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes

Ortíz¹,

Ramı́rez-Emiliano²,

Ramos-Rodríguez³

et al. 2016

WJD

View full text Add to dashboard Cite

AIMTo assess the relationship of brain-derived neurotrophic factor (BDNF) with cognitive impairment in patients with type 2 diabetes.METHODSThe study included 40 patients with diabetes mellitus type 2 (DM2), 37 patients with chronic kidney disease in hem dialysis hemodialysis therapy (HD) and 40 healthy subjects. BDNF in serum was quantified by ELISA. The Folstein Mini-Mental State Examination was used to evaluate cognitive impairment.RESULTSThe patients with DM2 and the patients in HD were categorized into two groups, with cognitive impairment and without cognitive impairment. The levels of BDNF showed significant differences between patients with DM2 (43.78 ± 9.05 vs 31.55 ± 10.24, P = 0.005). There were no differences between patients in HD (11.39 ± 8.87 vs 11.11 ± 10.64 P = 0.77); interestingly, ferritin levels were higher in patients with cognitive impairment (1564 ± 1335 vs 664 ± 484 P = 0.001). The comparison of BDNF values, using a Kruskal Wallis test, between patients with DM2, in HD and healthy controls showed statistical differences (P < 0.001).CONCLUSIONLow levels of BDNF are associated with cognitive impairment in patients with DM2. The decrease of BDNF occurs early and progressively in patients in HD.

show abstract

Section: Introductionmentioning

confidence: 99%

Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes

Ortíz¹,

Ramı́rez-Emiliano²,

Ramos-Rodríguez³

et al. 2016

WJD

View full text Add to dashboard Cite

show abstract

“…Not only is BDNF increasingly considered a neurotrophin, it is also seen as an immunotrophin, epitheliotrophin and metabotrophin (Chaldakov et al 2007), which would explain why, besides psychiatric and neurodegenerative diseases, somatic illnesses have also been related to BDNF. Somatic conditions that have been shown to correlate with BDNF levels mainly concern cardiovascular disease or cardiovascular risk factors (Ejiri et al 2005; Geroldi et al 2006; Hristova and Aloe, 2006; Suwa et al 2006; Krabbe et al 2007; Fujinami et al 2008), which is not surprising given that serum levels may be affected by lifestyle factors such as chronic or excessive alcohol use, lack of physical exercise and smoking (Chan et al 2008; Montag et al 2008; Tang et al 2008; Currie et al 2009; Umene-Nakano et al 2009).…”

Section: Introductionmentioning

confidence: 99%

Serum brain-derived neurotrophic factor: Determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people

Bus

Tendolkar

Franke

et al. 2011

The World Journal of Biological Psychiatry

View full text Add to dashboard Cite

ObjectivesBrain-derived neurotrophic factor (BDNF) is involved in major depressive disorder and neurodegenerative diseases. Clinical studies, showing decreased serum BDNF levels, are difficult to interpret due to limited knowledge of potential confounders and mixed results for age and sex effects. We explored potential determinants of serum BDNF levels in a community sample of 1230 subjects.MethodsMultiple linear regression analyses with serum BDNF level as the dependent variable were conducted to explore the effect of four categories of potential BDNF determinants (sampling characteristics, sociodemographic variables, lifestyle factors and somatic diseases) and of self-reported depressive symptoms (Beck's Depression Inventory (BDI).ResultsOur results show that BDNF levels decline with age in women, whereas in men levels remain stable. Moreover, after controlling for age and gender, the assays still showed lower serum BDNF levels with higher BDI sum scores. Effects remained significant after correction for two main confounders (time of sampling and smoking), suggesting that they serve as molecular trait factors independent of lifestyle factors.ConclusionsGiven the age-sex interaction on serum BDNF levels and the known association between BDNF and gonadal hormones, research is warranted to delineate the effects of the latter interaction on the risk of psychiatric and neurodegenerative diseases.

show abstract

“…BDNF and weight change is also supported by the role of this neurotrophin as a key mediator in the neuronal responses to external environmental factors such as dietary restriction [23]. Low levels of circulating BDNF are noted in individuals with obesity and type 2 diabetes mellitus, implying an unknown role for this neurotrophin in mediating the metabolism of glucose in obese patients [24]. …”

Section: Discussionmentioning

confidence: 99%

Effect of the rs10767664 Variant of the Brain-Derived Neurotrophic Factor Gene on Weight Change and Cardiovascular Risk Factors in Morbidly Obese Patients after Biliopancreatic Diversion Surgery

Luis

Izaola²,

Primo³

et al. 2016

Lifestyle Genomics

View full text Add to dashboard Cite

Background: The effect of the rs10767664 variant of the brain-derived neurotrophic factor gene on weight loss after bariatric surgery has not been evaluated. We decided to investigate the role of the rs10767664 variant on outcomes after biliopancreatic diversion surgery. Materials and Methods: A sample of 90 patients with morbid obesity without diabetes mellitus was operated. Biochemical and anthropometric evaluation were realized at basal visit and at each visit during 3 years (at 1, 2 and 3 years). Results: Initial percentage excess weight loss, body mass index, weight, waist circumference, fat mass, blood pressure, low-density lipoprotein cholesterol, total cholesterol, triglyceride levels, insulin and homeostasis model assessment for insulin resistance (HOMA-IR) improved. No differences in these changes were detected between the two genotypes (wild-type group AA vs. mutant group AT plus TT) in a dominant model. The improvement of insulin levels was lower in T-allele carriers than non-T-allele carriers (-2.8 ± 0.7 vs. -7.1 ± 0.9 UI/dl; p = 0.02). The decrease of fasting glucose (-13.4 ± 7.4 vs. -24.2 ± 5.2 mg/dl; p = 0.01) and HOMA-IR (-1.1 ± 0.3 vs. -0.5 ± 0.4 units; p = 0.02) were lower in T-allele carriers than non-T-allele carriers. Conclusion: Our data showed an association between the rs10767664 variant and metabolic response after weight loss. Non-T-allele carriers have a better improvement in glucose, insulin and HOMA-IR levels than T-allele carriers.

show abstract

Comment on: Krabbe KS, Nielsen AR, Krogh-Madsen R et al (2007) Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 50:431–438

Cited by 21 publications

References 10 publications

Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes

Brain-derived neurotrophic factor plasma levels and premature cognitive impairment/dementia in type 2 diabetes

Serum brain-derived neurotrophic factor: Determinants and relationship with depressive symptoms in a community population of middle-aged and elderly people

Effect of the rs10767664 Variant of the Brain-Derived Neurotrophic Factor Gene on Weight Change and Cardiovascular Risk Factors in Morbidly Obese Patients after Biliopancreatic Diversion Surgery

Contact Info

Product

Resources

About